Dexcom G7 for Continuous Glucose Monitoring
(DexcomG7 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a prospective longitudinal study to study the agreement between a continuous glucose monitoring system (CGMS) versus current blood glucose monitoring. Subjects in this study will have their blood glucose measured regularly every 1-3 hours with current methods in the Cardiovascular Intensive Care Unit (CVICU), and by Point of Care (POC) fingerstick glucose using the Accucheck Inform II on the regular floors, and the CGMS reading at the same time will be captured. Subjects will have measurements taken throughout their stay in the CVICU and on the regular floors. Agreement and correlation between systems, as well as errors, will be calculated.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on monitoring blood glucose levels, so it's best to ask the study team for guidance.
Is the Dexcom G7 Continuous Glucose Monitoring System safe for use in humans?
The Dexcom G7 Continuous Glucose Monitoring System has been evaluated for safety in adults with diabetes, and no serious adverse events were reported during a study involving 316 participants. However, previous models like the Dexcom G6 have been associated with skin reactions due to certain adhesive components.12345
What makes the Dexcom G7 Continuous Glucose Monitoring System unique compared to other treatments for diabetes?
What data supports the effectiveness of the Dexcom G7 Continuous Glucose Monitoring System treatment?
The Dexcom G7 Continuous Glucose Monitoring System has been shown to provide accurate glucose readings in adults with diabetes, with a mean absolute relative difference (MARD) of 8.2% for sensors placed on the arm and 9.1% for those on the abdomen. This means the system is reliable in tracking blood sugar levels, which can help people with diabetes manage their condition more effectively.148910
Who Is on the Research Team?
Lansang Cecilia, MD
Principal Investigator
The Cleveland Clinic
Are You a Good Fit for This Trial?
This trial is for patients who have undergone cardiac surgery and are being monitored in the Cardiovascular Intensive Care Unit (CVICU) or on regular floors. Participants must be eligible for regular blood glucose monitoring. Specific inclusion and exclusion criteria details were not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Dexcom G7 continuous glucose monitor and have their blood glucose measured regularly every 1-3 hours in the CVICU and on regular floors
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Dexcom G7
Dexcom G7 is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cleveland Clinic
Lead Sponsor
DexCom, Inc.
Industry Sponsor
Kevin Sayer
DexCom, Inc.
Chief Executive Officer since 2015
Bachelor’s and Master’s degrees in Accounting and Information Systems from Brigham Young University
Dr. Shelly Lane
DexCom, Inc.
Chief Medical Officer since 2023
MD from University of California, San Diego